Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Public prescription drug plan coverage for antiretrovirals and the potential cost to people living with HIV in Canada: a descriptive study.

Yoong D, Bayoumi AM, Robinson L, Rachlis B, Antoniou T.

CMAJ Open. 2018 Nov 27;6(4):E551-E560. doi: 10.9778/cmajo.20180058. Print 2018 Oct-Dec.

2.

High prevalence of syndemic health problems in patients seeking post-exposure prophylaxis for sexual exposures to HIV.

Morrison SA, Yoong D, Hart TA, MacPherson P, Bogoch I, Sivarajah V, Gough K, Naccarato M, Tan DHS.

PLoS One. 2018 May 23;13(5):e0197998. doi: 10.1371/journal.pone.0197998. eCollection 2018.

3.

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review.

Naccarato MJ, Yoong DM, Fong IW, Gough KA, Ostrowski MA, Tan DHS.

J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325957417752260. doi: 10.1177/2325957417752260.

PMID:
29385867
4.

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.

Tan DHS, Hull MW, Yoong D, Tremblay C, O'Byrne P, Thomas R, Kille J, Baril JG, Cox J, Giguere P, Harris M, Hughes C, MacPherson P, O'Donnell S, Reimer J, Singh A, Barrett L, Bogoch I, Jollimore J, Lambert G, Lebouche B, Metz G, Rogers T, Shafran S; Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network.

CMAJ. 2017 Nov 27;189(47):E1448-E1458. doi: 10.1503/cmaj.170494. No abstract available. Erratum in: CMAJ. 2018 Jun 25;190(25):E782.

5.

Dolutegravir and metformin: a case of hyperlactatemia.

Naccarato M, Yoong D, Fong IW.

AIDS. 2017 Sep 24;31(15):2176-2177. doi: 10.1097/QAD.0000000000001617. No abstract available.

PMID:
28906282
6.

Reply: Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir.

Yoong D, Naccarato M, Gough K.

Ann Pharmacother. 2017 Oct;51(10):931-932. doi: 10.1177/1060028017716693. Epub 2017 Jun 19. No abstract available.

PMID:
28627222
7.

Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir.

Yoong D, Naccarato M, Gough K.

Ann Pharmacother. 2017 Aug;51(8):713-714. doi: 10.1177/1060028017702677. Epub 2017 Mar 28. No abstract available.

PMID:
28351160
8.

Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis.

Yoong D, Naccarato M, Sharma M, Wilton J, Senn H, Tan DH.

Int J STD AIDS. 2016 Jul;27(8):608-16. doi: 10.1177/0956462415589896. Epub 2015 May 29.

PMID:
26025254
10.

Re: "Erythema Annulare Centrifugum due to Pegylated Interferon-α-2a plus Ribavirin Combination Therapy in a Patient with Chronic Hepatitis C Virus Infection".

Naccarato M, Yoong D, Solomon R, Ostrowski M.

J Cutan Med Surg. 2015 Jan-Feb;19(1):10. doi: 10.2310/7750.2014.14040. Epub 2015 Jan 1. No abstract available.

PMID:
25775656
11.

Selecting an antiretroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting.

Tan DH, Goddey-Erikefe B, Yoong D, Naccarato M, McIntyre S, Qureshi R, Gough K.

Infect Control Hosp Epidemiol. 2014 Mar;35(3):326-8. doi: 10.1086/675297. No abstract available.

PMID:
24521604
12.

Amiodarone and concurrent antiretroviral therapy: a case report and review of the literature.

Naccarato M, Yoong D, la Porte C, Fong I.

Antivir Ther. 2014;19(4):329-39. doi: 10.3851/IMP2715. Epub 2013 Dec 3. Review.

PMID:
24296729
13.

Non-occupational post-exposure prophylaxis for HIV at St Michael's Hospital, Toronto: a retrospective review of patient eligibility and clinical outcomes.

Chan AC, Gough K, Yoong D, Dimeo M, Tan DH.

Int J STD AIDS. 2013 May;24(5):393-7. doi: 10.1177/0956462412472826. Epub 2013 Jun 14.

PMID:
23970708
14.

Erythema annulare centrifugum-like eruption associated with pegylated interferon treatment for hepatitis C.

Naccarato M, Yoong D, Solomon R, Ostrowski M.

Dermatol Reports. 2013 Jul 29;5(1):e1. doi: 10.4081/dr.2013.e1. eCollection 2013 Jul 29.

15.

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Tseng A, Foisy M, Hughes CA, Kelly D, Chan S, Dayneka N, Giguère P, Higgins N, Hills-Nieminen C, Kapler J, la Porte CJ, Nickel P, Park-Wyllie L, Quaia C, Robinson L, Sheehan N, Stone S, Sulz L, Yoong D.

Can J Hosp Pharm. 2012 Mar;65(2):125-45. No abstract available.

16.

A potential drug-herbal interaction between Ginkgo biloba and efavirenz.

Naccarato M, Yoong D, Gough K.

J Int Assoc Physicians AIDS Care (Chic). 2012 Mar-Apr;11(2):98-100. doi: 10.1177/1545109711435364. Epub 2012 Feb 9.

PMID:
22323244
17.

A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.

Naccarato M, Yoong D, Kovacs C, Gough K.

Antivir Ther. 2012;17(3):589-92. doi: 10.3851/IMP1953. Epub 2011 Nov 4.

PMID:
22293514
18.

Outcomes of dosage adjustments used to manage antiretroviral drug interactions.

Park-Wyllie LY, Levine MA, Holbrook A, Thabane L, Antoniou T, Yoong D, Kam D, Bayoumi AM.

Clin Infect Dis. 2007 Oct 1;45(7):933-6. Epub 2007 Aug 20.

PMID:
17806064
19.

Severe bruising in an HIV-positive patient with haemophilia after using a needle-free gas-powered injection device.

Yoong D, Loufty M, Chin T, Bayoumi AM.

AIDS. 2007 Jul 11;21(11):1499-500. No abstract available.

PMID:
17589206
20.

Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.

Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, Rachlis A, Loutfy M.

HIV Med. 2005 Jul;6(4):284-90.

21.

Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series.

Antoniou T, Yoong D, Beique L, Chirhin S, Rachlis A, Gough K, Loutfy MR.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):126-8. No abstract available.

PMID:
15851924
22.

Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid.

Antoniou T, Gough K, Yoong D, Arbess G.

Clin Infect Dis. 2004 Mar 1;38(5):e38-40. Epub 2004 Feb 11.

PMID:
14986271

Supplemental Content

Support Center